vs
Cellebrite DI Ltd.（CLBT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Cellebrite DI Ltd.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$292.2M vs $207.3M），Ultragenyx Pharmaceutical Inc.净利率更高（-62.0% vs -103.5%，领先41.4%），Cellebrite DI Ltd.自由现金流更多（$60.8M vs $-100.8M），过去两年Cellebrite DI Ltd.的营收复合增速更高（72.8% vs 38.0%）
Cellebrite DI Ltd.是一家总部位于以色列佩塔提克瓦的数字取证企业，为执法机构、企业及服务供应商提供数字数据的采集、审阅、分析与管理工具，旗下核心产品系列为Cellebrite UFED。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CLBT vs RARE — 直观对比
营收规模更大
CLBT
是对方的1.4倍
$207.3M
净利率更高
RARE
高出41.4%
-103.5%
自由现金流更多
CLBT
多$161.6M
$-100.8M
两年增速更快
CLBT
近两年复合增速
38.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $292.2M | $207.3M |
| 净利润 | $-302.3M | $-128.6M |
| 毛利率 | 84.6% | — |
| 营业利润率 | 14.1% | -54.7% |
| 净利率 | -103.5% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $-1.50 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLBTRARE
| Q4 25 | — | $207.3M | ||
| Q3 25 | $292.2M | $159.9M | ||
| Q2 25 | $220.8M | $166.5M | ||
| Q1 25 | $89.6M | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | $232.1M | $139.5M | ||
| Q2 24 | $185.3M | $147.0M | ||
| Q1 24 | $71.2M | $108.8M |
净利润CLBTRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-302.3M | $-180.4M | ||
| Q2 25 | $36.9M | $-115.0M | ||
| Q1 25 | $-71.4M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | — | $-133.5M | ||
| Q2 24 | $-95.2M | $-131.6M | ||
| Q1 24 | $-40.6M | $-170.7M |
毛利率CLBTRARE
| Q4 25 | — | — | ||
| Q3 25 | 84.6% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 85.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 83.5% | — | ||
| Q2 24 | 84.1% | — | ||
| Q1 24 | 82.6% | — |
营业利润率CLBTRARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | 14.1% | -106.9% | ||
| Q2 25 | 12.1% | -64.8% | ||
| Q1 25 | 10.3% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 7.9% | -94.6% | ||
| Q2 24 | 11.7% | -79.1% | ||
| Q1 24 | 0.2% | -151.9% |
净利率CLBTRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | -103.5% | -112.8% | ||
| Q2 25 | 16.7% | -69.0% | ||
| Q1 25 | -79.7% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | — | -95.7% | ||
| Q2 24 | -51.4% | -89.5% | ||
| Q1 24 | -57.0% | -156.8% |
每股收益（稀释后）CLBTRARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | $-1.50 | $-1.81 | ||
| Q2 25 | $0.15 | $-1.17 | ||
| Q1 25 | $-0.36 | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | $-0.35 | $-1.40 | ||
| Q2 24 | $-0.48 | $-1.52 | ||
| Q1 24 | $-0.21 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $191.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $336.0M | $-80.0M |
| 总资产 | $690.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLBTRARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | $191.7M | $202.5M | ||
| Q2 25 | $326.1M | $176.3M | ||
| Q1 25 | $191.7M | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | $189.5M | $150.6M | ||
| Q2 24 | $178.6M | $480.7M | ||
| Q1 24 | $189.5M | $112.3M |
股东权益CLBTRARE
| Q4 25 | — | $-80.0M | ||
| Q3 25 | $336.0M | $9.2M | ||
| Q2 25 | $408.4M | $151.3M | ||
| Q1 25 | $336.0M | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | $34.2M | $346.8M | ||
| Q2 24 | $-40.2M | $432.4M | ||
| Q1 24 | $34.2M | $140.3M |
总资产CLBTRARE
| Q4 25 | — | $1.5B | ||
| Q3 25 | $690.6M | $1.2B | ||
| Q2 25 | $787.4M | $1.3B | ||
| Q1 25 | $690.6M | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $532.9M | $1.5B | ||
| Q2 24 | $556.6M | $1.6B | ||
| Q1 24 | $532.9M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $60.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 20.8% | -48.6% |
| 资本支出强度资本支出/营收 | 1.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $172.1M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CLBTRARE
| Q4 25 | — | $-99.8M | ||
| Q3 25 | $66.2M | $-91.4M | ||
| Q2 25 | $53.5M | $-108.3M | ||
| Q1 25 | $10.0M | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | $58.2M | $-67.0M | ||
| Q2 24 | $24.6M | $-77.0M | ||
| Q1 24 | $12.5M | $-190.7M |
自由现金流CLBTRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $60.8M | $-92.7M | ||
| Q2 25 | $47.5M | $-110.7M | ||
| Q1 25 | $8.5M | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | $55.3M | $-68.6M | ||
| Q2 24 | $21.0M | $-79.0M | ||
| Q1 24 | $11.4M | $-193.9M |
自由现金流率CLBTRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | 20.8% | -58.0% | ||
| Q2 25 | 21.5% | -66.5% | ||
| Q1 25 | 9.5% | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | 23.8% | -49.2% | ||
| Q2 24 | 11.3% | -53.7% | ||
| Q1 24 | 16.0% | -178.2% |
资本支出强度CLBTRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | 1.8% | 0.8% | ||
| Q2 25 | 2.7% | 1.5% | ||
| Q1 25 | 1.7% | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 1.3% | 1.2% | ||
| Q2 24 | 1.9% | 1.4% | ||
| Q1 24 | 1.5% | 3.0% |
现金转化率CLBTRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLBT
| Subscription services | $197.2M | 67% |
| Term-license | $60.8M | 21% |
| Professional services | $23.2M | 8% |
| Other non-recurring | $11.0M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
